Oppenheimer & CO Inc Astria Therapeutics, Inc. Transaction History

Oppenheimer & CO Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$6.99 - $16.69 $10,485 - $25,035	-1,500 Reduced 10.38%	12,944 $182,000
Q4 2023 Feb 13, 2024	SELL	$4.42 - $8.06 $366 - $668	-83 Reduced 0.57%	14,444 $110,000
Q2 2023 Aug 02, 2023	SELL	$8.33 - $13.72 $12,495 - $20,580	-1,500 Reduced 9.36%	14,527 $121,000
Q1 2023 May 10, 2023	BUY	$11.2 - $15.79 $123 - $173	11 Added 0.07%	16,027 $213,000
Q4 2022 Feb 07, 2023	SELL	$7.44 - $14.89 $13,392 - $26,802	-1,800 Reduced 10.1%	16,016 $238,000
Q3 2022 Nov 14, 2022	SELL	$2.97 - $10.34 $17,226 - $59,972	-5,800 Reduced 24.56%	17,816 $161,000
Q1 2022 May 12, 2022	BUY	$3.92 - $7.1 $7,056 - $12,780	1,800 Added 8.25%	23,616 $158,000
Q4 2021 Feb 02, 2022	BUY	$5.08 - $8.62 $48,600 - $82,467	9,567 Added 78.1%	21,816 $118,000
Q3 2021 Nov 12, 2021	BUY	$7.32 - $12.9 $89,662 - $158,012	12,249 New	12,249 $108,000

107

48.6M

48K

9.3K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $146M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.